Menu

Blog

Jan 16, 2024

CRISPR/Vertex gene editing drug cleared for beta-thalassemia

Posted by in categories: bioengineering, biotech/medical

Vertex Pharma (VRTX) announces FDA nod gene editing therapy, Casgevy, developed with CRISPR Therapeutics (CRSP) for beta-thalassemia (TDT).

Comments are closed.